(688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Issuance Results of the 1st Tranche of Sci-Tech Innovation Bonds for 2026
Filed with SSE · Stock code 688506 · · 2 pages · Chinese
Summary by 6ix AI
The bonds have a defined term and interest rate, with details provided in the announcement.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Sichuan Biokin Pharmaceutical Co., Ltd. on 6ix
Story so far
- (688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Inclusion of Yizekang (Izalontamab Brengitecan, BL-B01D1/iza-bren) in the Priority Review Program for Treatment of EGFR-TKI-Resistant, EGFR-Mutant Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for Yizekang (Izalontamab Brengitecan, BL-B01D1/iza-bren) in Combination with Radiotherapy for the Treatment of Locally Advanced Unresectable Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
- (688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Appointment of Securities Affairs Representative
Earlier from Sichuan Biokin Pharmaceutical
- (688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Inclusion of Yizekang (Izalontamab Brengitecan, BL-B01D1/iza-bren) in the Priority Review Program for Treatment of EGFR-TKI-Resistant, EGFR-Mutant Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for Yizekang (Izalontamab Brengitecan, BL-B01D1/iza-bren) in Combination with Radiotherapy for the Treatment of Locally Advanced Unresectable Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
- (688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Temporary Use of Certain Idle Raised Funds to Supplement Working Capital
- (688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Appointment of Securities Affairs Representative
- Announcement on Voluntary Disclosure of the Completion of Enrollment of the First Subject in the Phase III Clinical Trial of T-Bren for Injection (HER2 ADC) for the Treatment of HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Later from Sichuan Biokin Pharmaceutical
All Sichuan Biokin Pharmaceutical news releasesFollow Sichuan Biokin Pharmaceutical into a list and get an email when it puts out news.
Follow Sichuan Biokin Pharmaceutical